ArchiMed Acquires Natus Medical Incorporated

ARCHIMED Diagnostics Acquires 60% Stake in ARK Diagnostics

October 28, 2025

Medical Devices

ARCHIMED Diagnostics (ARCHIMED’s diagnostics team) has acquired a 60% stake in Fremont-based ARK Diagnostics from Soulbrain Holdings in a transaction valuing ARK at $428 million. Soulbrain retains and reinvests in a 40% stake and the deal includes a joint-venture agreement to accelerate ARK’s product development and global expansion.

Nihon Kohden Acquires 71.4% Stake in Ad‑Tech from ARCHIMED

November 26, 2024

Medical Devices

Nihon Kohden has acquired a 71.4% stake in NeuroAdvanced Corp., the parent of Ad‑Tech Medical Instrument Corporation, from ARCHIMED’s MED II fund, with ARCHIMED retaining a 28.6% minority stake and entering a joint venture with Nihon Kohden. The deal brings together Nihon Kohden’s EEG and monitoring platform with Ad‑Tech’s intracranial neuroelectrodes to strengthen epilepsy diagnostics and expand Ad‑Tech’s global reach across North America, Europe and Asia.

ARCHIMED (MED Platform II) Acquires Jeisys Medical

September 11, 2024

Medical Devices

ARCHIMED, via its MED Platform II fund, has agreed a ₩990 billion take-private acquisition of Jeisys Medical, a Seoul-based developer of energy-based aesthetic medicine devices. The transaction will delist Jeisys from the Korea Exchange and support the company’s international expansion, with founder Dong Hwan Kang reinvesting a material portion of his proceeds into the privatized business.

ARCHIMED Acquires Majority Stake in Germany's Zyto Group

January 12, 2021

Medical Devices

ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.

ArchiMed Acquires Majority Stake in NAMSA

September 1, 2020

Healthcare Services

ArchiMed, a healthcare-focused private equity firm, acquired a majority interest in NAMSA from the founding Gorski Family in an undisclosed equity recapitalization. NAMSA's president and senior management retained a significant double-digit stake; ArchiMed said the investment will support NAMSA's international growth and buy‑and‑build strategy to broaden services and accelerate expansion.

ARCHIMED Acquires 75% Stake in ActiGraph

May 18, 2020

Medical Devices

ARCHIMED (ArchiMed) has acquired a 75% stake in ActiGraph in an all-equity transaction, with management retaining 10% and other historic shareholders keeping 15%. The investment will fund ActiGraph's expansion into the regulated drug-development and clinical-trials market, accelerating product, regulatory and commercial capabilities; financial terms were not disclosed.